What is an intraductal papillary mucinous neoplasm (IPMN)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 17, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

What is an IPMN?

An intraductal papillary mucinous neoplasm (IPMN) is a mucin-producing pre-invasive tumor that grows within the pancreatic ducts, characterized by papillary epithelial proliferation that causes cystic dilation of the main pancreatic duct and/or its branches. 1, 2

Pathological Definition

IPMNs are mass-forming pre-invasive neoplasms (tumoral intraepithelial neoplasms) that must be greater than 1 cm in diameter to distinguish them from incidental microcysts and large pancreatic intraepithelial neoplasms (PanINs). 1

The defining histological features include:

  • Papillary epithelial proliferation within dilated pancreatic ducts filled with mucin 2
  • Friable papillary projections within dilated mucin-filled ducts 3
  • Thick mucin secretion that causes segmental or diffuse ductal dilatation 4

Spectrum of Disease

IPMNs represent an adenoma-carcinoma sequence, encompassing a spectrum from benign to malignant lesions:

  • Low-grade dysplasia → intermediate-grade dysplasia → high-grade dysplasia → invasive carcinoma 1
  • The lesions range from innocuous-appearing (formerly called "hyperplasia") to full-blown intramucosal carcinomatous lesions (formerly designated as "papillary adenocarcinoma"). 1

Anatomical Classification

IPMNs are classified into three types based on ductal involvement, which has critical implications for malignancy risk:

  • Branch duct type (BD-IPMN): Involves only the branch ducts; most are benign 4, 5
  • Main duct type (MD-IPMN): Involves the main pancreatic duct; frequently malignant with higher risk of progression 4, 5
  • Mixed type (MT-IPMN): Combines both branch and main duct characteristics 4, 5

The main duct type presents a significantly higher risk of malignant progression than the branch duct type. 4

Histological Subtypes

The American College of Surgeons classifies IPMNs into four main cell types, each with distinct morphological characteristics and genetic drivers: 3

  • Gastric type: Columnar cells with mucinous cytoplasm, simple and short papillae, and frequent pyloric gland-like elements 3
  • Intestinal type: Pseudostratified columnar cells with basophilic appearance and apical mucin, villous growth pattern similar to colonic adenomas 3
  • Pancreatobiliary type: Cuboidal cells with enlarged nuclei and scant mucin production, complex papillary configurations 3
  • Oncocytic type: Cuboidal cells with oncocytic cytoplasm arranged in 2-5 layers, complex arborescent papillae with intraepithelial lumens 3

Approximately 15% of cases present with overlapping characteristics and should be classified as "mixed." 3

Invasive Carcinoma

When IPMNs progress to invasive carcinoma, two main types are recognized:

  • Ductal/tubular invasive carcinoma: Atypical cells forming irregular and complex tubular or glandular structures 3
  • Colloid carcinoma: Muconodular pattern with distinct pools of mucin containing scant groups of carcinomatous cells 3

A critical diagnostic pitfall is distinguishing true invasive colloid carcinoma from duct rupture with mucin extrusion into the stroma, as this distinction dramatically affects patient prognosis and management. 3

Key Diagnostic Features

The main imaging characteristic distinguishing IPMN from other pancreatic lesions is dilatation of the pancreatic duct without the presence of an obstructing lesion. 6

IPMNs must be differentiated from:

  • Mucinous cystic neoplasms 2
  • Retention cysts 2
  • Intraductal tubular/tubulopapillary neoplasms 2
  • Large duct type invasive adenocarcinomas 2
  • Congenital, duplication, and paraduodenal wall cysts 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Intraductal Papillary Mucinous Neoplasm (IPMN) Diagnosis and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Histopathological Examination of IPMN

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Uptodate in the assessment and management of intraductal papillary mucinous neoplasms of the pancreas.

European review for medical and pharmacological sciences, 2017

Research

Intraductal papillary mucinous neoplasms of the pancreas.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2007

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.